NATCO PHARMA Financial Statement Analysis
|
||
|
The Revenues of NATCO PHARMA have increased by 10.77% YoY .
The Earnings Per Share (EPS) of NATCO PHARMA has increased by 35.80 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
NATCO PHARMA Last 5 Annual Financial Results
[BOM: 524816|NSE : NATCOPHARM]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹4,430 Cr | ₹3,999 Cr | ₹2,707 Cr | ₹1,945 Cr | ₹2,052 Cr |
| Expenses | ₹2,236 Cr | ₹2,247 Cr | ₹1,795 Cr | ₹1,681 Cr | ₹1,448 Cr |
| Operating Profit (Excl OI) | ₹2,194 Cr | ₹1,751 Cr | ₹912 Cr | ₹264 Cr | ₹604 Cr |
| Other Income | ₹357 Cr | ₹128 Cr | ₹129 Cr | ₹99 Cr | ₹106 Cr |
| Interest | ₹24 Cr | ₹19 Cr | ₹15 Cr | ₹18 Cr | ₹13 Cr |
| Depreciation | ₹235 Cr | ₹187 Cr | ₹164 Cr | ₹143 Cr | ₹117 Cr |
| Profit Before Tax | ₹2,291 Cr | ₹1,674 Cr | ₹862 Cr | ₹202 Cr | ₹580 Cr |
| Profit After Tax | ₹1,883 Cr | ₹1,388 Cr | ₹715 Cr | ₹170 Cr | ₹442 Cr |
| Consolidated Net Profit | ₹1,885 Cr | ₹1,388 Cr | ₹715 Cr | ₹170 Cr | ₹441 Cr |
| Earnings Per Share (Rs) | ₹105.33 | ₹77.56 | ₹39.19 | ₹9.32 | ₹24.16 |
| PAT Margin (%) | 39.54 | 32.05 | 24.83 | 7.67 | 21.23 |
| ROE(%) | 27.98 | 25.88 | 15.66 | 4.06 | 11.27 |
| ROCE(%) | 32.85 | 30.08 | 18.06 | 4.86 | 13.99 |
| Total Debt/Equity(x) | 0.04 | 0.06 | 0.03 | 0.09 | 0.06 |
Key Financials |
||
| Market Cap | : | ₹ 14,919.9 Cr |
| Revenue (TTM) | : | ₹ 4,395.8 Cr |
| Net Profit(TTM) | : | ₹ 1,695.2 Cr |
| EPS (TTM) | : | ₹ 94.7 |
| P/E (TTM) | : | 8.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NATCO PHARMA | 2.6% | -4.9% | -40% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.2% | 2.1% | -10.7% |
| DIVIS LABORATORIES | 0.3% | 6.4% | 8.7% |
| CIPLA | 6.8% | 5.6% | 5.2% |
| TORRENT PHARMACEUTICALS | 1.6% | -1.1% | 5.1% |
| DR REDDYS LABORATORIES | 4.6% | -2.5% | -4.3% |
| MANKIND PHARMA | 0% | -8.1% | -8.5% |
| ZYDUS LIFESCIENCES | 2.3% | -3.6% | -1.8% |
| LUPIN | 0.1% | -5.5% | -10.7% |
NATCO PHARMA Revenues
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 10.77 % |
| 5 Yr CAGR | 21.21 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹4,430 Cr | 10.77 | |
| Mar2024 | ₹3,999 Cr | 47.72 | |
| Mar2023 | ₹2,707 Cr | 39.20 | |
| Mar2022 | ₹1,945 Cr | -5.23 | |
| Mar2021 | ₹2,052 Cr | - | |
NATCO PHARMA Operating Profit
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 25.26 % |
| 5 Yr CAGR | 38.06 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹2,194 Cr | 25.26 | |
| Mar2024 | ₹1,751 Cr | 92.10 | |
| Mar2023 | ₹912 Cr | 246.00 | |
| Mar2022 | ₹264 Cr | -56.36 | |
| Mar2021 | ₹604 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 13.08 % |
| 5 Yr CAGR | 13.91 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 49.53% | 13.08 | |
| Mar2024 | 43.8% | 30.05 | |
| Mar2023 | 33.68% | 148.56 | |
| Mar2022 | 13.55% | -53.94 | |
| Mar2021 | 29.42% | - | |
NATCO PHARMA Profit After Tax
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 35.81 % |
| 5 Yr CAGR | 43.80 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,885 Cr | 35.81 | |
| Mar2024 | ₹1,388 Cr | 94.09 | |
| Mar2023 | ₹715 Cr | 320.76 | |
| Mar2022 | ₹170 Cr | -61.44 | |
| Mar2021 | ₹441 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 23.37 % |
| 5 Yr CAGR | 16.82 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 39.54 % | 23.37 | |
| Mar2024 | 32.05 % | 29.08 | |
| Mar2023 | 24.83 % | 223.73 | |
| Mar2022 | 7.67 % | -63.87 | |
| Mar2021 | 21.23 % | - | |
NATCO PHARMA Earnings Per Share (EPS)
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 35.80 % |
| 5 Yr CAGR | 44.50 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹105 | 35.80 | |
| Mar2024 | ₹78 | 97.91 | |
| Mar2023 | ₹39 | 320.49 | |
| Mar2022 | ₹9.32 | -61.42 | |
| Mar2021 | ₹24 | - | |
NATCO PHARMA Return on Capital Employed (ROCE)
[BOM: 524816|NSE : NATCOPHARM]
| Y-o-Y | 9.21 % |
| 5 Yr CAGR | 23.79 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 32.85% | 9.21 | |
| Mar2024 | 30.08% | 66.56 | |
| Mar2023 | 18.06% | 271.60 | |
| Mar2022 | 4.86% | -65.26 | |
| Mar2021 | 13.99% | - | |
NATCO PHARMA Share Price vs Sensex
| Current Share Price | : | ₹833.1 |
| Current MarketCap | : | ₹ 14,919.9 Cr |
| Updated EOD on | : | Oct 23,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 2.6% |
-4.9% |
-40% |
| SENSEX | 2.4% |
2.3% |
4.4% |
NATCO PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE HEALTHCARE | 1.7% | -0.1% | 2.4% |
| BSE 500 | 1.6% | 1.1% | 1.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 MULTICAP INDIA MANUFACTURING 50:30:20 | 1.6% | -0.4% | 2.5% |
| NIFTY TOTAL MARKET | 1.6% | 1% | 1.3% |
| NIFTY 500 | 1.6% | 1.2% | 1.6% |
| NIFTY500 SHARIAH | 1.6% | -1.6% | -10% |
| NIFTY500 MULTICAP 50:25:25 | 1.4% | 0.6% | 0.5% |
You may also like the below Video Courses
FAQ about NATCO PHARMA Financials
How the annual revenues of NATCO PHARMA have changed ?
The Revenues of NATCO PHARMA have increased by 10.77% YoY .
How the Earnings per Share (EPS) of NATCO PHARMA have changed?
The Earnings Per Share (EPS) of NATCO PHARMA has increased by 35.80 % YoY .
Check out Intrinsic Value of Peers of NATCO PHARMA
Compare Stock Analytics of Peers of NATCO PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
